Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EDIT

EDIT - Editas Medicine Inc Stock Price, Fair Value and News

$2.06-0.05 (-2.37%)
Market Closed

10/100

EDIT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

EDIT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.73

Target 3M

$1.94

Target 6M

$1.84

EDIT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EDIT Price Action

Last 7 days

-2.8%

Last 30 days

-1.9%

Last 90 days

-31.6%

Trailing 12 Months

45.1%

EDIT RSI Chart

EDIT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EDIT Valuation

Market Cap

201.1M

Price/Earnings (Trailing)

-1.01

Price/Sales (Trailing)

4.68

Price/Free Cashflow

-1.11

EDIT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.73

Target 3M

$1.94

Target 6M

$1.84

EDIT Fundamentals

EDIT Revenue

Revenue (TTM)

43.0M

Rev. Growth (Yr)

-56.77%

Rev. Growth (Qtr)

261.43%

EDIT Earnings

Earnings (TTM)

-199.8M

Earnings Growth (Yr)

59.58%

Earnings Growth (Qtr)

52.82%

EDIT Profitability

Return on Equity

-1.5K%

Return on Assets

-99.05%

Free Cashflow Yield

-89.86%

EDIT Investor Care

Shares Dilution (1Y)

18.26%

Diluted EPS (TTM)

-2.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202535.9M39.4M43.0M0
202473.3M74.7M53.5M32.3M
202322.8M19.3M24.6M78.1M
202225.8M31.8M25.6M19.7M
202191.5M81.1M24.5M25.5M
202024.2M32.6M91.6M90.7M
201930.1M25.0M14.4M20.5M
201817.0M21.2M29.5M31.9M
20175.9M5.6M11.0M13.7M
20162.4M5.7M5.9M6.1M
20150001.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Editas Medicine Inc

EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEeditasmedicine.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES226

Editas Medicine Inc Frequently Asked Questions

EDIT is the stock ticker symbol of Editas Medicine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Editas Medicine Inc is 201.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check EDIT's fair value in chart for subscribers.

The fair value guage provides a quick view whether EDIT is over valued or under valued. Whether Editas Medicine Inc is cheap or expensive depends on the assumptions which impact Editas Medicine Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EDIT.

As of Wed Jan 28 2026, EDIT's PE ratio (Price to Earnings) is -1.01 and Price to Sales (PS) ratio is 4.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDIT PE ratio will change depending on the future growth rate expectations of investors.